E-Z-EM names new U.K. general manager

Article

Gastrointestinal contrast agent developer E-Z-EM of Westbury, NY, this month appointed David Wills as general manager for its U.K. subsidiary, E-Z-EM Ltd. of London. Wills plans to focus on bolstering the company’s share in the U.K. barium sulfate

Gastrointestinal contrast agent developer E-Z-EM of Westbury, NY, this month appointed David Wills as general manager for its U.K. subsidiary, E-Z-EM Ltd. of London. Wills plans to focus on bolstering the company’s share in the U.K. barium sulfate contrast market. He comes to E-Z-EM from Medtronic U.K. Ltd., where he served as business development manager for that firm’s peripheral vascular division. Wills brings 16 years of medical device sales experience to his new post.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.